A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome.
Summary
Paired lung-blood multi-omics in children with PARDS versus controls identified three convergent immune abnormalities characterizing severe disease, with evidence involving pulmonary CD8-related changes. Findings were validated using cytokine assays and in vitro models, advancing mechanistic understanding.
Key Findings
- High-dimensional multi-omics of paired pulmonary and blood samples distinguished severe PARDS from controls.
- Three convergent immune abnormalities characterize severe PARDS, including pulmonary CD8-related changes.
- Findings were validated via cytokine assays and in vitro models, supporting biological plausibility.
Clinical Implications
Improved endotyping may enable risk stratification and guide development of immunomodulatory therapies tailored to pediatric ARDS.
Why It Matters
Integrates multi-omics across pulmonary and systemic compartments to define immune programs driving severe pediatric ARDS, providing a mechanistic map for biomarker and target discovery.
Limitations
- Exact sample size and quantitative effect estimates are not specified in the provided abstract segment.
- Cross-sectional observational design limits causal inference.
Future Directions
Validate immune signatures in larger, multicentre pediatric cohorts and test targeted immunomodulatory strategies informed by identified programs.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - Observational comparative analysis (PARDS vs age-matched controls) with multi-omics and experimental validation.
- Study Design
- OTHER